Abstract :

Background & Aims: Metabolic syndrome (MetS), a combination of diverse metabolic disorders (hypertension, diabetes mellitus, high triglycerides, increased waist circumference, and low high density cholesterol, HDLc), is a well known public health problem worldwide, and its prevalence is increasing dramatically. MetS is a confirmed great risk factor for cardiovascular diseases.

Presently, limited information exists about incidence and the risk factors associated with metabolic syndrome (MetS) in patients with epilepsy.  We prospectively estimated the incidence of MetS in patients with epilepsy.

Methods: We recruited 322 participants, 161 patients with epilepsy and 161 healthy volunteers all of them free of any MetS criteria at the baseline and followed-up them for one year. New onset cases of MetS were defined according to the updated National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) criteria.

Results: Over a 1-year follow-up, we observed 8 incident cases of MetS (7 individuals in patients group and 1 individual in control group) resulting in an annual cumulative incidence rate of 2.5%. We observed 9 cases losses to follow up. Patients with epilepsy presented a higher risk of developing MetS (RR=7.00, 95% CI: 0.891 – 1.67, p=0.032) than in control group. Sedentariness was associated with higher risk for MetS (hazard ratio, HR=6.537, 95%; confidence interval, C.I=1.269-33.685, p value =0.025.

Conclusion: Anti-epileptic therapy combined with sedentariness increases the risk of developing MetS among patients with epilepsy. Holistic clinical management of patients with epilepsy will significantly contribute to MetS prevention.

---

Keywords :

anti-epileptic drugs, epilepsy, incidence, Metabolic syndrome

---

References :

1. K. Shimamoto, ‘[Metabolic syndrome and cardiovascular diseases].’, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, vol. 97, no. 3. pp. 591–597, 10-Mar-2008.
2. M. Šimunovit, J. Bodit, L. Milit, I. Unit, and V. Škrabit, ‘The Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors in Obese Children and Adolescents in Dalmatia: A Hospital Based Study’, hindawi.com, 2009.
3. E. Bonora, ‘The metabolic syndrome and cardiovascular disease’, Annals of Medicine, vol. 38, no. 1. Taylor and Francis A.S., pp. 64–80, 2006.
4. E. B.-A. of medicine and  undefined 2006, ‘The metabolic syndrome and cardiovascular disease’, Taylor Fr.
5. P. H.-T. in E. & Metabolism and  undefined 2009, ‘eNOS, metabolic syndrome and cardiovascular disease’, Elsevier.
6. S. A. Ritchie and J. M. C. Connell, ‘The link between abdominal obesity, metabolic syndrome and cardiovascular disease’, Elsevier.
7. S. M. Grundy, ‘Obesity, Metabolic Syndrome, and Cardiovascular Disease’, academic.oup.com, 2004.
8. A. Gil-Núñez, ‘The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence’, Cerebrovasc. Dis., vol. 24, no. 1, pp. 64–75, Nov. 2007.
9. B. Solymoss, M. Bourassa, … J. L.-C. artery, and  undefined 2003, ‘Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease’, journals.lww.com.
10. G. D. Kolovou, K. K. Anagnostopoulou, K. D. Salpea, and D. P. Mikhailidis, ‘The prevalence of metabolic syndrome in various populations’, American Journal of the Medical Sciences, vol. 333, no. 6. Elsevier, pp. 362–371, 01-Jun-2007.
11. S. G. Schorr, C. J. Slooff, R. Bruggeman, and K. Taxis, ‘The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year’, J. Psychiatr. Res., vol. 43, no. 13, pp. 1106–1111, 2009.
12. A. Gaitatzis, K. Carroll, A. Majeed, and J. W. Sander, ‘The epidemiology of the comorbidity of epilepsy in the general population’, Epilepsia, vol. 45, no. 12, pp. 1613–1622, Dec. 2004.
13. K. N.-N. treatment of epilepsy. S. Intech and  undefined 2011, ‘Adverse metabolic effect of antiepileptic drug treatment’, books.google.com.
14. E. Goodman, S. R. Daniels, J. A. Morrison, B. Huang, and L. M. Dolan, ‘Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents’, J. Pediatr., vol. 145, no. 4, pp. 445–451, Oct. 2004.
15. S. Nair, S. Harikrishnan, P. Sarma, S. T.- Seizure, and  undefined 2016, ‘Metabolic syndrome in young adults with epilepsy’, Elsevier.
16. L. H. Ronquillo and J. Francisco Tellez-Zenteno, ‘Obesity and its association with generalised epilepsy, idiopathic syndrome, and family history of epilepsy’, Wiley Online Libr., vol. 16, no. 3, pp. 343–353, Sep. 2014.
17. S. T, P. R, and L. J, ‘SenseWear-determined physical activity and sedentary behavior and metabolic syndrome.’, Med. Sci. Sports Exerc., vol. 45, no. 3, pp. 481–489, Mar. 2013.
18. A. Bankoski et al., ‘Sedentary activity associated with metabolic syndrome independent of physical activity’, Diabetes Care, vol. 34, no. 2, pp. 497–503, Feb. 2011.
19. C. L. Edwardson et al., ‘Association of Sedentary Behaviour with Metabolic Syndrome: A Meta-Analysis’, PLoS One, vol. 7, no. 4, p. e34916, Apr. 2012.
20. A. Verrotti, R. Manco, S. Agostinelli, … G. C.-, and  undefined 2010, ‘The metabolic syndrome in overweight epileptic patients treated with valproic acid’, Wiley Online Libr.
21. A. Dhir, S. Sharma, P. Jain, … B. B.-J. of pediatric, and  undefined 2015, ‘Parameters of metabolic syndrome in Indian children with epilepsy on valproate or phenytoin monotherapy’, ncbi.nlm.nih.gov.
22. B. L. Carter, R. E. Small, M. D. Mandel, and M. T. Starkman, ‘Phenytoin-induced hyperglycemia’, Am. J. Heal. Pharm., vol. 38, no. 10, pp. 1508–1512, Oct. 1981.
23. R. M. Nanau and M. G. Neuman, ‘Adverse drug reactions induced by valproic acid’, Clinical Biochemistry, vol. 46, no. 15. Elsevier, pp. 1323–1338, 01-Oct-2013.
24. S. A. Hamed, ‘Antiepileptic drugs influences on body weight in people with epilepsy’, Expert Review of Clinical Pharmacology, vol. 8, no. 1. Expert Reviews Ltd., pp. 103–114, 01-Jan-2014.
25. M. Vyas, B. Davidson, L. Escalaya, J. C.-E. research, and  undefined 2015, ‘Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review’, Elsevier.